FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

Opsens Inc. (« Opsens » or the « Corporation »)
2014 Cyrille-Duquet Street, Suite 125
Québec, Québec
G1N 4N6

2. Date of Material Change

October 2, 2014

3. News Release

A news release, in French and English versions, was issued through CNW Telbec on October 2, 2014, copies of which are attached hereto.

4. Summary of Material Change

Opsens receives Shonin approval from the Japanese Ministry of Health, Labor and Welfare ("MHLW") to market the OptoWire and the OptoMonitor, its products that measure Fractional Flow Reserve ("FFR") in patients with coronary artery disease.

5. Full Description of Material Change

5.1 Full Description of Material Change

Opsens announced that its Japanese distributor received Shonin approval from the Japanese Ministry of Health, Labor and Welfare ("MHLW") to market the OptoWire and the OptoMonitor, its products that measure Fractional Flow Reserve ("FFR") in patients with coronary artery disease.

This approval marks a pivotal milestone in Opsens' strategic growth plan to become a key player in the FFR market. The Company's Japanese distributor filed Opsens' FFR products with the MHLW back in January 2014. The approval came nine months later, which clearly demonstrates that Opsens' verification and validation process is complying with the most rigorous standards of the Japanese regulatory agency. The fast receipt of the approval can also be credited to the quality of our production installations and to the effectiveness of the quality control systems in place.

Obtaining Shonin approval was the final condition for the release of a milestone payment worth US$1 million from our Japanese partner. The cash reception of this milestone payment is expected to happen in the next few weeks.

5.2 Disclosure for Restructuring Transactions

Not applicable.

6. Reliance on Subsection 7.1(2) of Regulation 51-102

Not applicable.

7. Omitted Information

Not applicable.

8. Executive Officer

For additional information, please contact:
Mr. Thierry Dumas
Chief Financial Officer
Phone: (418) 682-9996

9. Date of Report

November 27, 2015

Opsens Inc.

by: *(s) Thierry Dumas*
Thierry Dumas, Chief Financial Officer

PRESS RELEASE
For Immediate Dissemination

OPSENS RECEIVE SHONIN APPROVAL TO MARKET FFR PRODUCTS IN JAPAN

Quebec City, Quebec, October 2, 2014 – Opsens Inc. ("Opsens") (TSX-V: OPS) is pleased to announce that its Japanese distributor received Shonin approval from the Japanese Ministry of Health, Labor and Welfare ("MHLW") to market the OptoWire and the OptoMonitor, our products that measure Fractional Flow Reserve ("FFR") in patients suffering from coronary artery disease.

"This receipt marks a pivotal milestone in our strategic growth plan to become a key player in the FFR market," stated Louis Laflamme, President and Chief Executive Officer of Opsens. "Our Japanese distributor filed our FFR products with the MHLW back in January 2014. The approval came nine months later, which clearly demonstrates that our verification and validation process was in line with the rigorous standards of the Japanese regulatory agency. The fast receipt of the approval can also be credited to the quality of our production systems and effectiveness of the quality control of these systems. The speed at which approval was granted allows us to anticipate with optimism approval in other key geographies".

Obtaining Shonin approval was the final condition for the release of a milestone payment worth US$1 million from our Japanese partner. The cash reception of this milestone payment is expected to happen in the next few weeks.

"Now that Opsens' FFR products may be commercialized in Japan, Opsens and its partner will proceed with a pre-commercial phase with a limited number of institutions in that territory. Our Japanese partner, a player in interventional cardiology in Japan, is at the head of well-established distribution channels that should facilitate penetration of Opsens' products in the Asian market," said Claude Belleville, Vice-President, Medical.

Opsens aims to become a key player in the guidewire FFR market with the OptoWire, a patented nitinol-based optical guidewire for FFR. The OptoWire provides intra-coronary blood pressure measurements with a unique, patented optical sensor. It is immune to adverse effects related to blood contact, and allows easy and dependable connectivity that leads to reliable FFR measurement. The OptoWire is also designed to provide cardiologists with a guidewire delivering optimized performance to navigate coronary arteries and reach blockages with ease. Based on industry sources, the FFR market represented over US$250 million in sales in 2013 and is expected to reach US$1 billion in the medium-term. Opsens is confident that it is well positioned to capitalize on this significant growth opportunity.

About Opsens Inc. (www.opsens.com)

Focusing on two main growth markets, FFR in medical instrumentation and oil and gas, Opsens develops, manufactures and installs systems to measure pressure, temperature and others parameters using fiber optic sensing technologies. These systems are designed around patented technologies that are effective and durable in extreme conditions.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

-30-

For further information, please contact:

Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996

Louis Laflamme, CPA, CA, President and Chief Executive Officer, 418.682.9996